Vanda Pharmaceuticals (VNDA) FCF Margin (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly FCF Margin of 97.53% in Q1 2026, down 89.03% quarter-over-quarter from 51.59% in Q4 2025, and down 3042.0% year-over-year from 3.31% in Q1 2025.
Vanda Pharmaceuticals' FCF Margin history runs 17 years deep, the most recent figure standing at 97.53% for Q1 2026.
- In Q1 2026, FCF Margin fell 3042.0% year-over-year to 97.53%; the TTM figure through Mar 2026 stood at 58.45% (down 2995.0% YoY), while the FY2025 annual figure was 51.1%, down 4293.0% from the prior year.
- FCF Margin came in at 97.53% for Q1 2026 at Vanda Pharmaceuticals, down from 51.59% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 50.8% in Q1 2023 to a low of 97.53% in Q1 2026.
- A 5-year average of 16.38% and a median of 8.8% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin jumped 4421 bps in 2023 and slumped 8304 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' FCF Margin stood at 14.19% in 2022, then tumbled by 162 bps to 8.8% in 2023, then surged by 57 bps to 3.82% in 2024, then tumbled by 1251 bps to 51.59% in 2025, then slumped by 89 bps to 97.53% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 97.53%, 51.59%, and 56.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -97.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.53% |
| Dec 31, 2025 | -51.59% |
| Sep 30, 2025 | -56.50% |
| Jun 30, 2025 | -29.57% |
| Mar 31, 2025 | -67.11% |
| Dec 31, 2024 | -3.82% |
| Sep 30, 2024 | -30.94% |
| Jun 30, 2024 | -13.94% |
| Mar 31, 2024 | 15.93% |
| Dec 31, 2023 | -8.80% |
| Sep 30, 2023 | -5.34% |
| Jun 30, 2023 | -28.82% |
| Mar 31, 2023 | 50.80% |
| Dec 31, 2022 | 14.19% |
| Sep 30, 2022 | 19.43% |
| Jun 30, 2022 | 8.53% |
| Mar 31, 2022 | 6.60% |
| Dec 31, 2021 | 38.92% |
| Sep 30, 2021 | 13.42% |
| Jun 30, 2021 | 27.57% |
| Mar 31, 2021 | 14.46% |
| Dec 31, 2020 | 27.10% |
| Sep 30, 2020 | 15.14% |
| Jun 30, 2020 | 38.25% |
| Mar 31, 2020 | -2.21% |
| Dec 31, 2019 | 15.96% |
| Sep 30, 2019 | 9.59% |
| Jun 30, 2019 | 34.29% |
| Mar 31, 2019 | 19.39% |
| Dec 31, 2018 | 28.73% |
| Sep 30, 2018 | 17.42% |
| Jun 30, 2018 | 9.12% |
| Mar 31, 2018 | 3.45% |
| Dec 31, 2017 | 7.40% |
| Sep 30, 2017 | 4.35% |
| Jun 30, 2017 | -6.86% |
| Mar 31, 2017 | -15.60% |
| Dec 31, 2016 | -4.92% |
| Sep 30, 2016 | 1.67% |
| Jun 30, 2016 | -9.05% |
| Mar 31, 2016 | -14.73% |
| Dec 31, 2015 | -3.36% |
| Sep 30, 2015 | -20.20% |
| Jun 30, 2015 | 43.31% |
| Mar 31, 2015 | 21.54% |
| Dec 31, 2014 | -89.29% |
| Sep 30, 2014 | -51.77% |
| Jun 30, 2014 | -339.79% |
| Mar 31, 2014 | -262.92% |
| Dec 31, 2013 | -139.47% |
| Sep 30, 2013 | -118.02% |
| Jun 30, 2013 | -97.27% |
| Mar 31, 2013 | -113.39% |
| Dec 31, 2012 | -174.95% |
| Sep 30, 2012 | -122.84% |
| Jun 30, 2012 | -147.55% |
| Mar 31, 2012 | -129.41% |
| Dec 31, 2011 | -148.55% |
| Sep 30, 2011 | -90.40% |
| Jun 30, 2011 | -75.63% |
| Mar 31, 2011 | -43.51% |
| Dec 31, 2010 | 106.14% |
| Sep 30, 2010 | -70.02% |